From Bench to Bedside: Discovery of the First FDA‐ Approved Antibody Therapeutic for Migraine (Amgen Biotech Seminar)

  • Starts: 3:00 pm on Tuesday, October 13, 2020
  • Ends: 4:00 pm on Tuesday, October 13, 2020
Join BU's BEST workshop where we will discuss the path of Aimovig (erenumab), a first‐in‐class antibody therapeutic for the prevention of migraine, from early discovery through development to delivery to patients.